Maternal Influenza Vaccination and Risk for Congenital Malformations
Authors:
- Athanasios A. KonstanteliasAKAthanasios A. Konstantelias
- Chrysanthi E. PitsaCPChrysanthi E. Pitsa
- Matthew E. FalagasMFMatthew E. Falagas
- 1 November 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 126 (5) , 1075-1084
Abstract
To systematically summarize the literature on maternal influenza vaccination and the risk for congenital malformations using the methodology of meta-analysis. PubMed, Scopus, and Embase databases (up to December 2014) as well as ClinicalTrials.gov (May 2015) and references of relevant articles were searched. The search strategy included combinations of the terms "influenza," "vaccin*," "pregnan*," "safe*," "adverse," "congenital," "malformation," "defect," and "anomal*." Eligible studies examined the association between antepartum or preconceptional maternal immunization with inactivated influenza vaccines (seasonal trivalent or monovalent H1N1) and the risk for congenital malformations. Studies with no or inappropriate control group (comparison with population background rates or other vaccine types) were excluded. The risk for congenital anomalies after influenza vaccination was examined in 15 studies: 14 cohorts (events per vaccinated compared with unvaccinated: 859/32,774 [2.6%] compared with 7,644/245,314 [3.1%]) and one case-control study (vaccinated per cases compared with controls: 1,351/3,618 [37.3%] compared with 511/1,225 [41.7%]). Eight studies reported on first-trimester immunization (events per vaccinated compared with unvaccinated: 258/4,733 [5.4%] compared with 6,470/196,054 [3.3%]). No association was found between congenital defects and influenza vaccination at any trimester of pregnancy (odds ratio [OR] 0.96, 95% confidence interval 0.86-1.07; 15 studies; I2=36) or at the first trimester (OR 1.03, 0.91-1.18; eight studies; I2=0). When assessing only major malformations, no increased risk was detected after immunization at any trimester (OR 0.99, 0.88-1.11; 12 studies; I2=31.5) or at the first trimester (OR 0.98, 0.83-1.16; seven studies; I2=0). Neither adjuvanted (OR 1.06, 0.95-1.20; five studies; I2=18.8) nor unadjuvanted vaccines (OR 0.89, 0.75-1.04; seven studies; I2=22.6) were associated with an increased risk for congenital defects. This systematic review did not indicate an increased risk for congenital anomalies after maternal influenza immunization adding to the evidence base on the safety of influenza vaccination in pregnancy.Keywords
This publication has 36 references indexed in Scilit:
- Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre studyBMJ, 2013
- Low Rate of Pandemic A/H1N1 2009 Influenza Infection and Lack of Severe Complication of Vaccination in Pregnant Women: A Prospective Cohort StudyPLOS ONE, 2012
- AdimFlu-S® influenza A (H1N1) vaccine during pregnancy: The Taiwanese Pharmacovigilance SurveyVaccine, 2012
- Safety of Hepatitis B, Pneumococcal Polysaccharide and Meningococcal Polysaccharide Vaccines in PregnancyDrug Safety, 2012
- Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self‐reporting of serious adverse events and pregnancy outcomesBritish Journal of Clinical Pharmacology, 2011
- Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern HemisphereEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- H1N1 2009 influenza virus infection during pregnancy in the USAThe Lancet, 2009
- Effectiveness of Maternal Influenza Immunization in Mothers and InfantsNew England Journal of Medicine, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986